Establishing Quality Product Supply of Chlorhexidine for Umbilical Cord Care through Local Production Global Maternal Newborn Health Conference October.

Slides:



Advertisements
Similar presentations
Basic Principles of GMP
Advertisements

Quality Assurance Processes for TB Drugs. GDF Quality Assurance Processes.
Quality Assurance Policy RHSC, SSWG Addis Ababa, Ethiopia 21 June 2011 Morten Sorensen, UNFPA PSB.
Policy on Quality Assurance for Single and Limited- Source Pharmaceuticals Nairobi, Kenya, 20 – 24 February 2006.
Rational Use of Injections within National Drug Policies World health organisation Essential Drugs and Medicines Policy Safe Injection Global Network Cairo.
APIs – global business developments Gian Mario Baccalini EFCG Board Member, Chairman of EFCG Pharma Business Committee President, B&P Development Srl,
UNICEF Medicines Supply Strengthening WHO Technical Briefing Seminar on Essential Medicines and Health Products Tuesday 29 October 2013 Technical Specialist.
USAID Update 2014 Bureau for Global Health Christine Malati, PharmD
Slide 1 of 19D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
IPC meeting June 2014 Dr Joelle DAVIAUD, Quality Assurance Specialist Model Quality Assurance System for procurement agencies.
Good Manufacturing Practices for Blood Establishments
Management of Change Control. Overview Changes – Good or bad? Forced or voluntary? The Importance of Change Control Major Changes to both legacy company.
NATIONAL DRUG AUTHORITY - UGANDA | Slide 1 of February 2010, Geneva, Switzerland How the African NMRAs are benefiting from the WHO medicines prequalification.
March, 2012 CORPORATE PRESENTATION. The essence of life…
Public Health, Innovation and Intellectual Property Improving access to medicines through local production: Some New Development I P C Meeting, Copenhagen.
AIM 2030 Access to Innovative Medicines Draft concept for a new World Bank-led multi-stakeholder initiative August 2014, Andreas Seiter.
Technology Transfer & Quality
Options for national/regional production of generic medicines Wilbert Bannenberg, MD MPH Zambia TRIPS workshop 3 Oct 2013.
Update and future directions for prequalification of medicines WHO HQ, Geneva, 4 February 2008 Dr Lembit Rägo Coordinator Quality Assurance and Safety:
1 Directorate of Industry Relations, Analysis and Policy (DIRAP) Paul Herring, Director “CASE FOR CANADIAN DEFENCE INDUSTRIAL POLICY” 27 February 2012.
World Health Organization
Deeper IBM Global Business Services © Copyright IBM Corporation 2008 Investor’s Cafe Investor-driven marketing of your location October 8 th 2008.
PRODUCT TRANSFER.
Veiovis LifeSciences Pvt Ltd
Summary from the Economics Track With thanks to all track participants, presenters, rapporteurs, moderators and organizers.
Options for national/regional production of generic medicines Wilbert Bannenberg, MD MPH Lesotho TRIPS workshop 14 Aug 2014.
And Pharmaceuticals Health Technology Technical Cooperation for Essential Drugs and Traditional Medicine Challenges of Medicine Regulation in Africa Global.
RHSC Meeting Kampala, May 2010 Quality for Medicines The Global Fund approach Sophie Logez Manager, QA and Data Quality Pharmaceutical Management.
Approval Mechanism for Suppliers of Malaria Drugs and Nets Presentation by Dr Maryse Dugué RBM Partnership Secretariat, Malaria Medicines & Supplies Services.
Important informations
ACCESS TO MEDICINES - POLICY AND ISSUES
1 Regulatory Aspects of Pharmaceutical Excipients PQRI Workshop Nick Buhay Acting Director Division of Manufacturing and Product Quality Office of Compliance.
1 WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies Tuesday 1 November 2011 Technical Specialist Henrik K.Nielsen, Medicines and Nutrition.
Gaps from the Perspective of NGOs/ Foundations/PDPs IoM Workshop: International Regulatory Harmonization Amid Globalization of Biomedical Research & Medical.
WHO Prequalification of Medicines: a gateway to the global pharmaceutical market Introduction 28 June 2014, Shanghai Milan Smid.
UNICEF Medicines Supply Strengthening WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies Tuesday 30 October 2012 Technical Specialist.
Drug Management of Second-line anti-TB drugs through the Green Light Committee mechanism for programmes funded by the Global Fund to Fight Against AIDS,
The WHO Prequalification of Medicines Program - Introduction Tony Gould Manager, Prequalification of Medicines Program WHO.
3rd WHO Prequalification Stakeholders Meeting :Diagnostics 3rd Stakeholders Meeting on Prequalification Geneva, 4th February 2008 Update on Prequalification.
1 CHALLENGES IN REGULATING QUALITY AND RATIONAL USE OF ANTIBIOTICS ALLIANCE FOR THE PRUDENT USE OF ANTIBIOTICS: INAGURAL MEETING COURTYARD.
Responsibilities of Sponsor, Investigator and Monitor
Ensuring quality of medicines procured with Global Fund resources HIV AIDS conference Satellite on Essential Medicines for HIV AIDS Mexico 6 August 2008.
PHARMACEUTICAL INDUSTRY
Port of Cape Town Development Plans
ANNUAL PRODUCT REVIEW Patchara Kootiratrakarn Independent consultant.
Responsibilities of Sponsor, Investigator and Monitor
MECHANICAL PARTS FROM INDIA: Low Cost & Safe Procurement
EAST AFRICAN COMMUNITY MEDICINES REGULATORY HARMONIZATION (EAC-MRH) PROJECT PROGRESS NAIROB I - KENYA By: EAC - Secretariat.
WHO’s prioritised research agenda for the prevention and control of NCDs prioritises
ICH-GCP Avinash Kondawar M. Pharm Lead CRA
The WHO Prequalification of Medicines Programme Capacity building agenda Dr Milan Smid.
QUALITY CHALLENGES Rohan Patel Head of Quality Assurance
Leela Khanal Project Director JSI Research & Training Institute, Inc.
Overview of vaccines prequalification
7.1% Chlorhexidine Digulconate for Umbilical Cord Care
GDF Quality Assurance Processes
Managing Procurement and Logistics of HIV/AIDS Drugs and Related Supplies Introduction and Overview May 30 to June 4, 2005 Abuja, Nigeria.
UNICEF Medicine Supply Systems Strengthening
Global Drug Facility: Providing Access to Medicines and Commodities for Tuberculosis Thomas Moore Manager GDF Geneva, 19 November 2009.
Dr Manisha Shridhar Regional Advisor WHO-SEARO
Prequalification of HIV/AIDS products and manufacturers
Port of Cape Town Development Plans
The Next Frontier for Public Health Medicines Market
An Enabling Business Environment and A Strategic Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
Synergies between NDCs & SDGs; Integration into National Planning
WORKSHOP ON OPTIMAL PROCUREMENT OF AFFORDABLE AND QUALITY ASSURED LIFE-SAVING COMMODITIES FOR MATERNAL HEALTH KAMPALA, UGANDA - REGULATORY STATUS AND QUALITY.
An Enabling Business Environment and A Strategy and Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
Re-inspection of production sites: preparation of CAPA plans and their implementation GMP-inspection. Part , Quality director, Maklakova Olga.
GMP Legal Framework in Kyrgyzstan
Manufacture of Sterile Medicinal Products: ‘Annex 1’ - DRAFT
Presentation transcript:

Establishing Quality Product Supply of Chlorhexidine for Umbilical Cord Care through Local Production Global Maternal Newborn Health Conference October 2015 Mutsumi Metzler PATH

Major supply-side strategies Working with a global manufacturer. Working with local/regional manufacturers and establishing regional production hubs in selected countries.

Working with local/regional manufacturers Increasing production capability and capacity in low- and middle-income countries (LMICs). Existence of manufacturers with regional distribution network. Opportunities for further local capacity development. Product characteristics suitable for local production. Tailoring to local needs (e.g., packaging).

Procurers and providers Ensuring product quality is a multi-layered and multi-disciplinary effort Regulatory authority Acquisition of raw materials from quality sources Production of the finished product in compliance with GMP Product release after proper QC Registration according to in-country regulations Pre-purchase/sale inspections Proper use Manufacturers Procurers and providers

Chlorhexidine Working Group approach Select and work with qualified and committed manufacturers in countries where local production is feasible. Develop standard information and materials for use by manufacturers, regulators, and procurers.

Three major steps to establish supply of quality product in LMICs Assess the optimal way to establish product supply. Select qualified and committed manufacturers in countries where local production is feasible. Assist selected manufacturers to produce and register a quality chlorhexidine product.

Assessing the optimal way to establish product supply Assess the optimal way to establish product supply. Select qualified manufacturers in countries where local production is feasible. Assist selected manufacturers to produce and register a quality chlorhexidine product. Capability and capacity of pharmaceutical companies Strength of pharmaceutical industry. Experience in producing gels and/or solutions or chlorhexidine-based products. Affordability Domestic market size. Duties on imported API and other raw materials. Sustainability Possibility of exporting.

Selecting qualified and committed manufacturers Assess the optimal way to establish product supply. Select qualified and committed manufacturers in countries where local production is feasible. Assist selected manufacturers to produce and register a quality chlorhexidine product. Issue an expression of interest (EOI). Send a questionnaire to manufacturers who respond to the EOI to select a short list of manufacturers. Perform on-site manufacturing facility assessment and business due diligence to select manufacturers that qualify for further technical assistance.

Assisting manufactures until product registration Assess the optimal way to establish product supply. Select qualified and committed manufacturers in countries where local production is feasible. Assist selected manufacturers to produce and register a quality chlorhexidine product. Perform in-depth GMP assessment and create corrective and preventive action (CAPA) plans. Follow up with manufacturers to ensure that CAPA plans are properly implemented. Assist with product development if required. Assist creation and submission of regulatory dossiers if required.

2015 status Countries which have local production Lomus Pharmaceuticals Kathmandu, Nepal 2010 GlaxoSmithKline Brentford, England Evaluating TA and gap supply support ACI Limited Dhaka, Bangladesh 2015 Assessment underway 2014/2015 Galentic Pharmaceuticals Mumbai, India Available through UNICEF Supply Drugfield Pharmaceuticals Songo‐Atta, Nigeria 2014 Universal Corporation Regulatory approval pending 2015 Countries which have local production Countries which decided to import the product PATH and the Promoting the Quality of Medicines (PQM) program implemented by the US Pharmacopeial Convention (USP) are working to establish local and regional manufacturing hubs for chlorhexidine in Asia and Africa

Commercial availability of 7.1% chlorhexidine digluconate Solution UNICEF Supply Division catalogue ACI Limited (Bangladesh) Gel Drugfield Pharmaceuticals Ltd. (Nigeria) Lomus Pharmaceuticals Pvt. Ltd. (Nepal) Currently, liquid and gel forms of 7.1% chlorhexidine digluconate are available from these sources.

Documents created for manufacturers, procurers, and regulators Monographs Monograph for chlorhexidine gluconate topical solution included in USP-NF. Monograph for chlorhexidine gluconate topical gel currently available for public comment in PF on USP website. Standardized patient information leaflet. Key consideration for procurers.

CWG technical assistance page http://www. healthynewbornnetwork CWG technical assistance page http://www.healthynewbornnetwork.org/page/chlorhexidine-umbilical-cord- care-hub

Lawrence Evans, USP/PQM Thank you! Mutsumi Metzler, PATH Patricia Coffey, PATH Lawrence Evans, USP/PQM http://www.healthynewbornnetwork.org/page/chlor hexidine-umbilical-cord-care-hub